ORY-1001
- Generic Name
- ORY-1001
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2
- CAS Number
- 1401966-39-9
- Unique Ingredient Identifier
- XC0UT08SNJ
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Conditions
- Accelerated Phase Myeloproliferative NeoplasmEssential ThrombocythemiaMyeloproliferative Neoplasm, Not Otherwise SpecifiedBlast Phase Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary MyelofibrosisSecondary Myelofibrosis
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT06661915
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Buccal Swab
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06514261
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States
Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 12
- Registration Number
- NCT06502145
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanOther: Questionnaire Administration
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06357182
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Conditions
- Extensive Stage Lung Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06287775
- Locations
- 🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Oryzon Genomics S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT05546580
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
- Conditions
- Small-cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT05420636
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02913443
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇨🇦The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada
🇪🇸Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.